Brocasipal en es it fr

Brocasipal Brand names, Brocasipal Analogs

Brocasipal Brand Names Mixture

  • No information avaliable

Brocasipal Chemical_Formula


Brocasipal RX_link

Brocasipal fda sheet

Brocasipal FDA

Brocasipal msds (material safety sheet)

Brocasipal MSDS

Brocasipal Synthesis Reference

No information avaliable

Brocasipal Molecular Weight

269.381 g/mol

Brocasipal Melting Point

156-157 oC

Brocasipal H2O Solubility

Sparingly soluble in water

Brocasipal State


Brocasipal LogP


Brocasipal Dosage Forms

Tablet (extended-release)

Brocasipal Indication

Indicated for the treatment of Parkinson's disease.

Brocasipal Pharmacology

Orphenadrine is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. Orphenadrine is an anticholinergic with a predominantly central effect and only a weak peripheral effect. In addition, it has mild antihistaminic and local anaesthetic properties. Parkinson's syndrome is the consequence of a disturbed balance between cholinergic and dopaminergic neurotransmission in the basal ganglia caused by a decrease in dopamine. Orphenadrine restores the physiological equilibrium and has a favourable effect on the rigidity and tremor of Parkinson's disease and Parkinsonian syndromes. The effect is somewhat less on bradykinesia.

Brocasipal Absorption

Orphenadrine is almost completely absorbed in the gastrointestinal tract.

Brocasipal side effects and Toxicity

Oral, mouse LD50 = 100 mg/kg; oral, rat LD50 = 255 mg/kg

Brocasipal Patient Information

No information avaliable

Brocasipal Organisms Affected

Humans and other mammals